Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Renewed global threat by the novel SARS-CoV-2 variants ‘XBB, BF.7, BQ.1, BA.2.75, BA.4.6’: A discussion
Ranjan K. Mohapatra, Ahmed Mahal, L. V. Simhachalam Kutikuppala, et al.
Frontiers in Virology (2022) Vol. 2
Open Access | Times Cited: 19

Showing 19 citing articles:

The SARS-CoV-2 Omicron recombinant subvariants XBB, XBB.1, and XBB.1.5 are expanding rapidly with unique mutations, antibody evasion, and immune escape properties – an alarming global threat of a surge in COVID-19 cases again?
Chiranjib Chakraborty, Manojit Bhattacharya, Hitesh Chopra, et al.
International Journal of Surgery (2023) Vol. 109, Iss. 4, pp. 1041-1043
Open Access | Times Cited: 32
SARS-CoV-2 journey: from alpha variant to omicron and its sub-variants
Dima Hattab, Mumen F. A. Amer, Zina M. Al‐Alami, et al.
Infection (2024) Vol. 52, Iss. 3, pp. 767-786
Open Access | Times Cited: 13
Next-generation treatments: Immunotherapy and advanced therapies for COVID-19
Jenny Andrea Arévalo-Romero, Sandra M. Chingaté-López, Bernardo Camacho, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e26423-e26423
Open Access | Times Cited: 8
The SARS‐CoV‐2 Omicron Variant and its Multiple Sub‐lineages: Transmissibility, Vaccine Development, Antiviral Drugs, Monoclonal Antibodies, and Strategies for Infection Control – a Review
Ranjan K. Mohapatra, Sarika Verma, Venkataramana Kandi, et al.
ChemistrySelect (2023) Vol. 8, Iss. 9
Open Access | Times Cited: 16
Global threat from novel SARS-CoV-2 variants, BF.7, XBB.1.5, BQ.1, and BQ.1.1: variants of concern?
Ryan Varghese, Dileep Kumar, Rohit Sharma
Human Cell (2023) Vol. 36, Iss. 3, pp. 1218-1221
Open Access | Times Cited: 16
Chemical and spectroscopic characterization of (Artemisinin/Querctin/ Zinc) novel mixed ligand complex with assessment of its potent high antiviral activity against SARS-CoV-2 and antioxidant capacity against toxicity induced by acrylamide in male rats
Samy M. El‐Megharbel, Safa H. Qahl, Bander Albogami, et al.
PeerJ (2024) Vol. 12, pp. e15638-e15638
Open Access | Times Cited: 3
COVID’s future: Viral multi-lineage evolution and the dynamics of small epidemic waves without seasonality in COVID-19
Yamin Sun, Min Wang, Fengying Wei, et al.
Journal of Biosafety and Biosecurity (2023) Vol. 5, Iss. 3, pp. 96-99
Open Access | Times Cited: 9
Analyzing the emerging patterns of SARS‐CoV‐2 Omicron subvariants for the development of next‐gen vaccine: An observational study
Ranjan K. Mohapatra, Snehasish Mishra, Venkataramana Kandi, et al.
Health Science Reports (2023) Vol. 6, Iss. 10
Open Access | Times Cited: 9
Indian Biosimilars and Vaccines at Crossroads–Replicating the Success of Pharmagenerics
Sunita Panda, Puneet Kumar Singh, Snehasish Mishra, et al.
Vaccines (2023) Vol. 11, Iss. 1, pp. 110-110
Open Access | Times Cited: 8
COVID-19 Prognosis from Chest X-ray Images by using Deep Learning Approaches: A Next Generation Diagnostic Tool
Madhumita Pal, Smita Parija, Ganapati Panda, et al.
Journal of Pure and Applied Microbiology (2023) Vol. 17, Iss. 2, pp. 919-930
Open Access | Times Cited: 7
COVID‐19 vaccines and their underbelly: Are we going the right way?
Bhabani Sankar Satapathy, Gurudutta Pattnaik, Rudra Narayan Sahoo, et al.
Health Science Reports (2023) Vol. 6, Iss. 9
Open Access | Times Cited: 7
A computational method for anti-SARS-CoV-2 antibodies neutralization power: A blueprint with monoclonal antibody Sotrovimab (Preprint)
Dana Ashoor, Maryam Marzouq, M. Dahmani Fathallah
JMIR Bioinformatics and Biotechnology (2024) Vol. 5, pp. e58018-e58018
Open Access | Times Cited: 1
COVID-19 Era and the Constantly Reemerging Novel SARS-CoV-2 Variants Calls for Special Attention for the Geriatrics: A Real Challenge
L. V. Simhachalam Kutikuppala, Venkataramana Kandi, Ashish K. Sarangi, et al.
Geriatrics (2022) Vol. 7, Iss. 6, pp. 143-143
Open Access | Times Cited: 6
In silico evaluation of anti SARS-CoV-2 antibodies neutralization power: A blueprint with monoclonal antibody Sotrovimab
Dana Ashoor, Maryam Marzouq, M. Dahmani Fathallah
Research Square (Research Square) (2023)
Open Access | Times Cited: 3
Analysis of the protective efficacy of approved COVID-19 vaccines against Omicron variants and the prospects for universal vaccines
Keda Chen, Ling Zhang, Zhongbiao Fang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 3
A computational method for anti-SARS-CoV-2 antibodies neutralization power: A blueprint with monoclonal antibody Sotrovimab (Preprint)
Dana Ashoor, Maryam Marzouq, M. Dahmani Fathallah
(2024)
Open Access
Immunization against Medically Important Human Coronaviruses of Public Health Concern
Nabil Awni Nimer, Seema N Nimer
Canadian Journal of Infectious Diseases and Medical Microbiology (2024) Vol. 2024, Iss. 1
Open Access
A Strategic Framework of SARS‐CoV‐2 Genomic Surveillance in Bangladesh
Mohammad Jubair, Md Mobarok Hossain, Mst. Noorjahan Begum, et al.
Influenza and Other Respiratory Viruses (2024) Vol. 18, Iss. 10
Open Access
A predictive language model for SARS-CoV-2 evolution
Enhao Ma, Xuan Guo, Mingda Hu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access
Page 1

Scroll to top